Media
University College London appoints the next Director of the UCL Cancer Institute - October 2024
Professor Attard is appointed as the new Director of the UCL Cancer Institute
Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - October 2024
Nicholas James and Gerhardt Attard discuss findings from the STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors.
STAMPEDE2 Trial Explores Combination Niraparib and Abiraterone in mHSPC - October 2024
Sarah Howlett & Mahaz Kayani were interviewed by Dr Zachary Klaassen regarding the STAMPEDE2 platform trial, focusing on Arm N - niraparib and abiraterone for metastatic hormone-sensitive prostate cancer.
Blue Earth Therapeutics Announces Clinical Research Collaboration with UCL to Develop Innovative Alpha-labelled Radioligand Therapy (RLT) for Prostate Cancer - July 2024
UCL signed a clinical research collaboration with Blue Earth Therapeutics to study an Actinium-based radioligand therapy. Professor Attard will be leading the clinical trial resulting from this initiative.
The Prostate Cancer Clinical Masterclass - October 2022 to September 2023
The Prostate Cancer Clinical Masterclass Series is co-chaired by Dr Sumit Subudhi and Professor Attard with monthly videos from a total of 24 guest speakers who are leading prostate cancer clinicians. Watch out for Gert's episode in February.
https://prostatecancer.clinicalcommsgroup.com/
GU CONNECT - November 2022
Professor Attard joined fellow experts in GU oncology to discuss incorporating PARP inhibitor into clinical practice for prostate cancer.
UroToday ESMO 2022 interview - October 2022
Gert was interviewed by Ashley Ross, Feinberg School of Medicine, Chicago, USA, to discuss the results from the associations of transcriptome-wide gene expression signatures with outcomes in advanced prostate cancer patients treated with ADT or ADT and abiraterone, in STAMPEDE.
UroToday ESMO 2022 interview - September 2022
Gert and Marina were interviewed by Alicia Morgans, Dana-Farber Cancer Institute, Boston, USA, to discuss the results from their ESMO 2022 presentations relating to outcomes for metastatic prostate cancer patients treated with ADT, ADT and abiraterone or ADT, abiraterone and enzalutamide as part of the STAMPEDE trial and the associations of transcriptome-wide gene expression signatures with outcomes in advanced prostate cancer patients treated with ADT or ADT and abiraterone, also in STAMPEDE.
Medicine Matters ASCO GU 2022 - February 2022
Gert discusses the results of the MAGNITUDE trial evaluating the upfront addition of niraparib to abiraterone in men with metastatic castration-resistant prostate cancer harbouring homologous recombination repair gene alterations which reported at ASCO GU.
PCR grant explainer - January 2022
Gert and Emily talk about their Prostate Cancer Research-funded project developing a test to choose treatment for individual patients as part of the STAMPEDE trial.
https://www.youtube.com/watch?v=GDxfOaSirag
UroToday ESMO 2021 interview - September 2021
Gert spoke to Alicia Morgans to discuss the combined analysis from two comparisons in the STAMPEDE platform which he presented during the Presidential Symposium at ESMO 2021. This assessed the role of abiraterone with or without enzalutamide added to androgen deprivation therapy compared to ADT alone for men with high-risk non-metastatic prostate cancer.